Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sean Kalloo

Nephrology New York, NY Medical Doctor

NPI 1912160250 CMS profile 41106

622 W 168Th St, New York, NY 10032

Open in the dashboard

General payments

$61,142

216 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$9,230 paid to institutions, not to them · program year 2024

Through program year 2025, Sean Kalloo of New York, NY is reported in the CMS Open Payments database as having received $61,142 across 216 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $9,230 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,938 38
2024 General $1,130 31
2023 General $1,100 24
2022 General $3,206 11
2021 General $11,233 18
2020 General $11,783 29
2019 General $30,753 65

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sean Kalloo
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Sean Kalloo were reported at $1,938. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Sean Kalloo Nephrology median Middle half National median
2019 $30,753 $236 $90–$588 $163
2020 $11,783 $135 $46–$364 $114
2021 $11,233 $202 $67–$551 $132
2022 $3,206 $242 $77–$695 $149
2023 $1,100 $254 $84–$766 $160
2024 $1,130 $300 $99–$852 $164
2025 $1,938 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Fresenius USA Marketing, Inc. $51,693 68 payments
  2. GlaxoSmithKline, LLC. $2,760 1 payment
  3. Penumbra, Inc. $1,482 44 payments
  4. Medtronic, Inc. $1,227 27 payments
  5. Bard Peripheral Vascular, Inc. $995 23 payments
  6. Fresenius USA Manufacturing, Inc. $900 1 payment
  7. Argon Medical Devices, Inc. $687 25 payments
  8. Baxter Healthcare $592 5 payments
  9. Boston Scientific Corporation $232 3 payments
  10. Balt USA, LLC $125 5 payments
  11. Other $448 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Honoraria $33,750 13 payments
  2. Compensation for serving as faculty or as a speaker for a medical education program $11,800 9 payments
  3. Food and Beverage $7,849 173 payments
  4. Travel and Lodging $4,604 19 payments
  5. Consulting Fee $3,140 2 payments
Products named General payments · program years 2019–2025
  1. Indigo System $576 9 payments
  2. Emprint $406 9 payments
  3. Indigo $399 10 payments
  4. Non-Franchise (NOF) - NonProduct $380 1 payment
  5. OSTEOCOOL RF ABLATION SYSTEM $370 9 payments
  6. ELLIPSYS VASCULAR ACCESS SYSTEM $334 5 payments
  7. RUBY Coil $239 11 payments
  8. CLEANER $214 7 payments
  9. POD $202 6 payments
  10. Clot Management $201 7 payments
  11. Other $2,675 80 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

32

Median for Nephrology: 954

Drug cost

$2,171

Median for Nephrology: $127,050

Branded share of claims

0%

Median for Nephrology: 17.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sevelamer Carbonate Generic 20 $1,682
Midodrine Hcl Generic 12 $489

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,003 Part D prescribers listed as Nephrology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$63,785

Medicare's payments for the services billed

Medicare patients

114

Average age 66

Services billed

452

49 women, 65 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 75%
Diabetes 65%
Heart failure 63%
Ischemic heart disease 58%
Arthritis 48%
Atrial fibrillation 39%
Depression 39%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

216 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nephrology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record